3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Squamous Cell Carcinoma of Head and Neck
43
Lung Neoplasms
35
Oropharyngeal Neoplasms
22
Urinary Bladder Neoplasms
20
Head and Neck Neoplasms
18
Nasopharyngeal Carcinoma
17
Carcinoma
16
Biliary Tract Neoplasms
15
Small Cell Lung Carcinoma
14
Neoplasm Metastasis
14
Cholangiocarcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Esophageal Squamous Cell Carcinoma
13
Colorectal Neoplasms
13
Pancreatic Neoplasms
12
Neoplasms
12
Uterine Cervical Neoplasms
11
Carcinoma, Squamous Cell
11
Ovarian Neoplasms
10
Mouth Neoplasms
9
Laryngeal Neoplasms
9
Gallbladder Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Transitional Cell
8
Hypopharyngeal Neoplasms
7
Esophageal Neoplasms
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Mesothelioma, Malignant
6
Interventions
Carboplatin
3
selpercatinib
1
repotrectinib
1
pembrolizumab
1
durvalumab
1
atezolizumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Kyphoplasty
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
Cisplatin
×
90 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled